ReviewClinical & developmental immunology2011
Current immunotherapeutic approaches in pancreatic cancer.
Review in Clinical & developmental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.Nature medicine · 2026Trial
- Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.World journal of gastroenterology · 2015Trial
- Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine.Journal of cancer research and clinical oncology · 2015Trial
- Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.Cancer immunology research · 2014Trial
- Assessing the treatment of pancreatic ductal adenocarcinoma by deuterium metabolic imaging: a preclinical study.Magma (New York, N.Y.) · 2026Article
- Anti-cancer Potential of Scopoletin Derivatives Across Diverse Cancer Cell Lines: A Comprehensive Review.Current drug discovery technologies · 2026Review
- Advances in cancer nanovaccines: a focus on colorectal cancer.Nanomedicine (London, England) · 2025Review
- IL-2 promotes expansion and intratumoral accumulation of tumor infiltrating dendritic cells in pancreatic cancer.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- Efficacy of bivalentHeliyon · 2022Article
- The impact of tumor associated macrophages on tumor biology under the lens of mathematical modelling: A review.Frontiers in immunology · 2022Review
- Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.BMC cancer · 2021Article
- Fungi, host immune response, and tumorigenesis.American journal of physiology. Gastrointestinal and liver physiology · 2021Review
- Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2021Article
- Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.Journal of biomedical materials research. Part A · 2021Article
- The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor.Clinical and translational radiation oncology · 2020Article
- Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.The oncologist · 2020Article
- Review
- Marine natural products in the discovery and development of potential pancreatic cancer therapeutics.Advances in cancer research · 2019Review
- Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.